Catalyst
Slingshot members are tracking this event:
Sarepta Therapeutics (SRPT) Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SRPT | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Srp-4053, Srp-4045, Dmd, Duchenne Muscular Dystrophy, Exon 45, 53 Skipping
